Pluristem (Israel) Performance
| PSTI Stock | ILS 1,786 40.00 2.19% |
The company holds a Beta of 0.59, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pluristem's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pluristem is expected to be smaller as well. At this point, Pluristem has a negative expected return of -0.12%. Please make sure to check Pluristem's kurtosis, daily balance of power, and the relationship between the skewness and accumulation distribution , to decide if Pluristem performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pluristem has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 9.2 M | |
| Total Cashflows From Investing Activities | -7.3 M |
Pluristem |
Pluristem Relative Risk vs. Return Landscape
If you would invest 199,000 in Pluristem on September 14, 2024 and sell it today you would lose (20,400) from holding Pluristem or give up 10.25% of portfolio value over 90 days. Pluristem is generating negative expected returns and assumes 4.8368% volatility on return distribution over the 90 days horizon. Simply put, 43% of stocks are less volatile than Pluristem, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Pluristem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pluristem's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pluristem, and traders can use it to determine the average amount a Pluristem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0253
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PSTI |
Estimated Market Risk
| 4.84 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pluristem is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pluristem by adding Pluristem to a well-diversified portfolio.
Pluristem Fundamentals Growth
Pluristem Stock prices reflect investors' perceptions of the future prospects and financial health of Pluristem, and Pluristem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pluristem Stock performance.
| Return On Equity | -0.87 | |||
| Return On Asset | -0.37 | |||
| Operating Margin | (202.13) % | |||
| Current Valuation | 9.75 M | |||
| Shares Outstanding | 32.35 M | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 499.87 X | |||
| EBITDA | (48.42 M) | |||
| Cash And Equivalents | 10.54 M | |||
| Cash Per Share | 0.70 X | |||
| Total Debt | 23.85 M | |||
| Book Value Per Share | 1.18 X | |||
| Cash Flow From Operations | (30.91 M) | |||
| Earnings Per Share | (1.46) X | |||
| Total Asset | 93.54 M | |||
| Retained Earnings | (156 M) | |||
| Current Asset | 39 M | |||
| Current Liabilities | 5 M | |||
About Pluristem Performance
By analyzing Pluristem's fundamental ratios, stakeholders can gain valuable insights into Pluristem's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pluristem has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pluristem has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel. PLURISTEM THERAPEU operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 172 people.Things to note about Pluristem performance evaluation
Checking the ongoing alerts about Pluristem for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pluristem help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pluristem generated a negative expected return over the last 90 days | |
| Pluristem has high historical volatility and very poor performance | |
| Net Loss for the year was (49.87 M) with profit before overhead, payroll, taxes, and interest of 23 K. | |
| Pluristem has accumulated about 10.54 M in cash with (30.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7. |
- Analyzing Pluristem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pluristem's stock is overvalued or undervalued compared to its peers.
- Examining Pluristem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pluristem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pluristem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pluristem's stock. These opinions can provide insight into Pluristem's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pluristem Stock analysis
When running Pluristem's price analysis, check to measure Pluristem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pluristem is operating at the current time. Most of Pluristem's value examination focuses on studying past and present price action to predict the probability of Pluristem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pluristem's price. Additionally, you may evaluate how the addition of Pluristem to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |